Deeptech factory

DIOTHERIS

Diotheris develops anti-infective microbes

Diotheris develops bacterial therapies of the human skin and mucosal microbiome against pathogenic bacteria. The first suite of products targets Staphyloccocus aureus including MRSA (Methicillin resistant S aureus).

CEO : Simon Baeriswyl

Création : june 2020

Effectif : 4

Localisation : Paris

Marché(s) : Health, Biotech

www.diotheris.com

#StaphyloccusAureus #Microbiome #AntibioticResistance

TECHNO / PRODUITS

NASOFLORE Prevent is an « LBP » (live biotherapeutic product) composed of bacterial straints isolated from the human nose microbiome that have demonstrated a strong growth inhibiting activity against Staphylococcus aureus, including MRSA (Methicillin-resistant S. aureus ) in the laboratory and in preclinical models of living skin.

PORTEFEUILLE PRODUITS

  • NASOFLORE Prevent

APPLICATIONS

NASOFLORE Prevent inhibits nasal colonization by Staphylcoccus aureus in order to prevent in a natural fashion self-infections caused by this germ. The multiple applicaitons include prevention of post-operative infections and prevention of MRSA colonization in high-risk environments.

AVANTAGES

NASOFLORE Prevent is simple to use, can be administered as preventive treatment and does not lead to emergence of antibiotic resistance.